Bronchiectasis: an update on current pharmacotherapy and future perspectives

Bibliography

• Wilson R. Bronchiectasis. In: Gibson GJ, et al. editors, Respiratory medicine. Volume 2. 3rd edition. Elsevier Science Ltd, London; 2003
   Google Scholar
• Management of bronchiectasis. Drug Ther Bull 2003;41(12):91-5
   Google Scholar
• Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis Non-CF Guideline Group. British thoracic society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):1-58
   PubMed Web of Science ®Google Scholar
• Cole P, Wilson R. Host–microbial interrelationships in respiratory infection. Chest 1989;95:217S-21S
   Web of Science ®Google Scholar
• Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57(1):15-19
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
   PubMed Web of Science ®Google Scholar
• Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxicillin given in standard or high doses orally or by inhalation. Thorax 1986;41:559-65
   PubMed Web of Science ®Google Scholar
• Chan TH, Ho SS, Lai CK, et al. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chemotherapy 1996;42:150-6
   Google Scholar
• Lam WK, Chau PY, So SY, et al. Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. Respir Med 1989;83:299-303
   Google Scholar
• Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
   PubMed Web of Science ®Google Scholar
• Tsang KW, Chan WM, Ho PL, et al. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respir J 1999;14:1206-9
   PubMed Web of Science ®Google Scholar
• Brambilla C, Kastanakis S, Knight S, Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992;11(2):118-24
   PubMed Web of Science ®Google Scholar
• Mehta AP, Phutane L, Patel MH, et al. Comparative study of amoxycillin and amoxycillin/clavulanic acid in lower respiratory infections. J Assoc Physicians India 1991;39(3):251-3
   Google Scholar
• Abu Hassan J, Saadiah S, Roslan H, Zainudin BM. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology 1999;4:423-6
   Google Scholar
• Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2003;(3):CD003572
   Google Scholar
• Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001;(2):CD002163
   Google Scholar
• Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
   PubMed Web of Science ®Google Scholar
• Kellett F, Niven RM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105:1831-5
   PubMed Web of Science ®Google Scholar
• Nicolson C, Stirling R, Borg B, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106:661-7
   PubMed Web of Science ®Google Scholar
• Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006;(2):CD002996
   Google Scholar
• Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843-8
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005;10:46-56
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, Young I. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008;31:765-72
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K, et al. Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis. Eur Respir J 2003;22(Suppl 45):430
   Google Scholar
• Bilton D, Daviskas E, Anderson S, et al. A phase III randomised study of the efficacy and safety of inhaled dry powder mannitol (Bronchitol) for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
   PubMed Web of Science ®Google Scholar
• Crockett A, Cranston JM, Alpers JH, Latiner KM. Mucolytics for bronchiectasis (Review). Cochrane Database Syst Rev 2001;(1):CD001289
   Google Scholar
• Olivieri D, Ciaccia A, Marangio E, et al. Role of bromhexine in exacerbations of bronchiectasis. Respiration 1991;58:117-21
   PubMed Web of Science ®Google Scholar
• Wills PJ, Wodehouse T, Corkery K, Mallon K. Short-term recombinant human DNase in bronchiectasis. Am J Respir Crit Care Med 1996;154:413-17
   PubMed Web of Science ®Google Scholar
• O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase 1. Chest 1998;113:1329-34
   PubMed Web of Science ®Google Scholar
• Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis (Review). Cochrane Database Syst Rev 2009;(1):CD000996
   Google Scholar
• Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-7
   PubMed Web of Science ®Google Scholar
• Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60:239-43
   PubMed Web of Science ®Google Scholar
• Elborn JS, Johnston B, Allen F, et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992;86(2):121-4
   PubMed Web of Science ®Google Scholar
• Martınez-Garcia M, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna J. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006;100:1623-32
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia M, Soler-Cataluna J, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141:461-8
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
   PubMed Web of Science ®Google Scholar
• Pizzutto S, Upham J, Yerkovich S, Chang A. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010;(4):CD007525
   Google Scholar
• Tamaoki J, Chiyotani A, Kobayashi K, et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992;145(3):548-52
   PubMed Web of Science ®Google Scholar
• Llewellyn-Jones CG, Johnson M, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
   PubMed Web of Science ®Google Scholar
• Vandermeer M, Thomas A, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012;205:13-32
   PubMed Web of Science ®Google Scholar
• Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013;107:524-33
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. BMJ 1957;2:255-9
   PubMedGoogle Scholar
• Sobel S, Lichter EA, Davis JC, et al. Adverse reactions to tetracycline, penicillin and an oleandomycin-penicillin mixture used in the long-term therapy of chronic pulmonary disease. Am J Med Sci 1962;243:341-53
   Google Scholar
• Cherniack N, Vosti K, Dowling H, et al. Long-term treatment of bronchiectasis and chronic bronchitis; a controlled study of the effects of tetracycline, penicillin, and an oleandomycinpenicillin mixture. AMA Arch Intern Med 1959;103(3):345-53
   Google Scholar
• Dowling H, Mellody M, Lepper M, Jackson G. Bacteriologic studies of the sputum in patients with chronic bronchitis and bronchiectasis. Results of continuous therapy with tetracycline, penicillin, or an oleandomycin-penicillin mixture. Am Rev Respir Dis 1960;81:329-39
   Google Scholar
• Currie DC, Garbett ND, Chan KL, et al. Double-blind randomised study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990;76:799-816
   PubMedGoogle Scholar
• Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999;13:361-4
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
   PubMed Web of Science ®Google Scholar
• Altenburg J, De Graaff C, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The bat randomized controlled trial. JAMA 2013;309(12):1251-9
   PubMed Web of Science ®Google Scholar
• Serisier D, Martin M, McGuckin M, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. The bless randomized controlled trial. JAMA 2013;309(12):1260-7
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. NEJM 2012;366(20):1881-90
   PubMed Web of Science ®Google Scholar
• Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155:2024-9
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107-15
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44
   PubMed Web of Science ®Google Scholar
• Serisier D, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-17
   PubMed Web of Science ®Google Scholar
• Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-80
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan J, Doherty C, et al. A randomised controlled trial of nebulised gentamicin in non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-49
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstrutive pulmonary disease. Am J Respir Crit Care Med 2013;188(10):1224-31
   PubMed Web of Science ®Google Scholar
• Hill AT, Bilton D, Brown J, et al. British thoracic society quality standards for clinically significant bronchiectasis in adults July 2012. Br Thorac Soc Rep 2012;4:1-16
   Google Scholar
• Adjemian J, Olivier K, Seitz A, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185(8):881-6
   PubMed Web of Science ®Google Scholar
• Olivier K, Weber D, Lee J, et al. Non-tuberculous mycobacterium. Am J Respir Crit Care Med 2003;167(6):828-34
   PubMed Web of Science ®Google Scholar
• Schembri S, Williamson P, Short P, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346:1235-46
   PubMed Web of Science ®Google Scholar
• Mandal P, Sidhu M, Donaldson L, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33
   PubMed Web of Science ®Google Scholar